Abstract 1378
Background
In MONARCH 3, a randomized, double-blind, phase 3 trial; continuous dosing of abemaciclib in combination with an AI (anastrozole or letrozole) conferred significant clinical benefit to postmenopausal women with HR+, HER2- ABC. We here report data from an additional 12 months of follow-up in this trial including analysis for clinically prognostic subgroups (Di Leo et al., 2018).
Methods
From the 31 October 2018 data cutoff, exploratory intermediate efficacy parameters including time to subsequent chemotherapy ([TCT] time from randomization to first chemotherapy [CT]) and time to second disease progression ([PFS2] time from randomization to discontinuation date of first post-discontinuation treatment [PDT], or starting date of the secondPDT, or death) were assessed. TCT and PFS2 were analyzed using the Kaplan-Meier method in the intent to treat (ITT) and subgroups previously identified as significantly prognostic.
Results
In the ITT population, updated PFS was 28.2 vs 14.8 months (HR [95% CI]: 0.525 [0.415, 0.665]; p<.0001) in the abemaciclib vs placebo arms, respectively. A higher number of patients discontinued the study in the placebo arm as compared to the abemaciclib arm, thereby starting a PDT. Systemic PDT was received by 178 (54%) patients in the abemaciclib arm and 123 (74.5%) in the placebo arm, of which 93 (28.4%) and 82 (49.7%) received CT respectively. Addition of abemaciclib to AI deferred the initiation of CT both in the ITT (HR [95% CI]: 0.513 [0.380, 0.691]; p<.0001) and in subgroups (Table). PFS2 was prolonged in the abemaciclib arm (HR [95% CI]: 0.637 [0.495, 0.819]; p<.0004). Consistent with the ITT population, PFS2 favored the abemaciclib arm across all subgroups of prognostic factors (Table). Safety profile was generally consistent with previously disclosed results.Table:
326P
TCT | PFS2 | |||||
---|---|---|---|---|---|---|
Abemaciclib + AI Events/N | Placebo + AI Events/N | HR (95% CI) | Abemaciclib + AI Events/N | Placebo + AI Events/N | HR (95% CI) | |
ITT | ||||||
93/328 | 82/165 | 0.513 (0.380, 0.691) | 152/328 | 106/165 | 0.637 (0.495, 0.819) | |
ECOG PS | ||||||
1 | 34/136 | 36/61 | 0.342 (0.214, 0.548) | 64/136 | 45/61 | 0.504 (0.344, 0.740) |
0 | 59/192 | 46/104 | 0.639 (0.435, 0.940) | 88/192 | 61/104 | 0.762 (0.549, 1.059) |
Bone-only disease | ||||||
Yes | 13/69 | 16/40 | 0.440 (0.211, 0.914) | 21/69 | 23/40 | 0.523 (0.289, 0.945) |
No | 80/259 | 66/125 | 0.495 (0.357, 0.686) | 131/259 | 83/125 | 0.660 (0.501, 0.871) |
Liver metastases | ||||||
Yes | 21/47 | 21/31 | 0.572 (0.313, 1.048) | 32/47 | 25/31 | 0.677 (0.401, 1.142) |
No | 72/281 | 61/134 | 0.504 (0.358, 0.709) | 120/281 | 81/134 | 0.663 (0.500, 0.881) |
Progesterone receptor status | ||||||
Positive | 66/255 | 57/128 | 0.529 (0.371, 0.753) | 115/255 | 78/128 | 0.694 (0.520, 0.927) |
Negative | 25/70 | 24/36 | 0.414 (0.236, 0.725) | 35/70 | 27/36 | 0.537 (0.325, 0.889) |
Tumor grade | ||||||
High | 22/65 | 21/32 | 0.369 (0.203, 0.672) | 27/65 | 23/32 | 0.418 (0.240, 0.730) |
Intermediate/Low | 52/179 | 48/96 | 0.512 (0.345, 0.757) | 86/179 | 63/96 | 0.671 (0.484, 0.931) |
Treatment-free interval | ||||||
<36 months | 15/44 | 18/32 | 0.465 (0.234, 0.924) | 21/44 | 24/32 | 0.506 (0.281, 0.910) |
≥36 months | 32/95 | 18/41 | 0.798 (0.448, 1.422) | 48/95 | 24/41 | 0.895 (0.548, 1.461) |
Conclusions
Addition of abemaciclib to AI prolonged PFS2 and TCT in the ITT and all prognostic subgroups.
Clinical trial identification
NCT02246621.
Editorial acknowledgement
Medical writing support was provided by Anchal Sood and editorial assistance by Rod Everhart of Syneos Health, and funded by Eli Lilly and Company.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
M. Martín: Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly and Company; Honoraria (self): Taiho Oncology; Honoraria (self): Pharmamar; Honoraria (self): Roche/Genentech. S. Johnston: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): Puma Biotechnology; Speaker Bureau / Expert testimony: Eisai. J. Huober: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy: Hexal; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy: Abbvie. A. Di Leo: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy, Travel / Accommodation / Expenses: Puma Biotechnology. V.A. Andre: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. H.R. Martin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. M.C. Hardebeck: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. M.P. Goetz: Honoraria (self): Genomic Health; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly and Company; Advisory / Consultancy: Biovica; Advisory / Consultancy: Novartis; Advisory / Consultancy: Sermonix; Advisory / Consultancy: Context Pharm; Research grant / Funding (institution): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
5489 - Local immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy
Presenter: xijin lin
Session: Poster Display session 2
Resources:
Abstract
1653 - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.
Presenter: Clémence Brun
Session: Poster Display session 2
Resources:
Abstract
5206 - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.
Presenter: Per Pfeiffer
Session: Poster Display session 2
Resources:
Abstract
2992 - Clinical impact of mucinous and poorly differentiated tumors on the outcome of patients with stage II colon cancer: a TOSCA subgroup analysis
Presenter: Gerardo Rosati
Session: Poster Display session 2
Resources:
Abstract
4753 - Exercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study
Presenter: Hong Jun Kim
Session: Poster Display session 2
Resources:
Abstract
2735 - Bevacizumab plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cancer (CC): Updated analysis of stage II disease from the AVANT Phase III Randomized trial by the GERCOR Group
Presenter: Aimery De Gramont
Session: Poster Display session 2
Resources:
Abstract
1843 - Multicenter Validation of the Postoperative Carcinoembryonic Antigen Combined Prognostic Model for Stage Ⅲ Colon Cancer
Presenter: Ji Zhu
Session: Poster Display session 2
Resources:
Abstract
2554 - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.
Presenter: Kaissa Ouali
Session: Poster Display session 2
Resources:
Abstract
3285 - Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Presenter: Philip Falk
Session: Poster Display session 2
Resources:
Abstract
3905 - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer
Presenter: Krittiya Korphaisarn
Session: Poster Display session 2
Resources:
Abstract